ACM
NBIX icon

Acrisure Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Acrisure Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,398
Closed -$243K – 159
2023
Q1 		$243K Buy
+2,398
New +$250K 0.25% 187

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acrisure Capital Management's NBIX Position: Q2 2023 in Review

Acrisure Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 2,398 shares — an estimated $243K sold.

Acrisure Capital Management first reported a position in NBIX in Q1 2023 and held it in 1 quarter. The position peaked at $243K in Q1 2023. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Acrisure Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • Acrisure Capital Management sold 2,398 Neurocrine Biosciences shares in Q2 2023, an estimated $243K.
  • Acrisure Capital Management first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 1 quarter.
  • Acrisure Capital Management's Neurocrine Biosciences position peaked at $243K in Q1 2023.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Acrisure Capital Management's 13F filing for Q2 2023.